AR085398A1 - Ureas asimetricas y usos medicos de las mismas - Google Patents
Ureas asimetricas y usos medicos de las mismasInfo
- Publication number
- AR085398A1 AR085398A1 ARP120100611A ARP120100611A AR085398A1 AR 085398 A1 AR085398 A1 AR 085398A1 AR P120100611 A ARP120100611 A AR P120100611A AR P120100611 A ARP120100611 A AR P120100611A AR 085398 A1 AR085398 A1 AR 085398A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituents
- group
- heteroarylalkyl
- heterocycloalkyl
- arylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Compuestos, composiciones y métodos para la prevención y/o tratamiento de enfermedades cuya fisiopatología está mediada por el receptor de ghrelina.Reivindicación 1: Un compuesto caracterizado porque responde a la fórmula (1), o una sal aceptable farmacéuticamente o aducto del mismo, donde: R se selecciona entre el grupo que consiste en arilo, arilalquilo, anillo carbocíclico, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, opcionalmente sustituido con uno o más sustituyentes R103 independientes; R1 se selecciona entre el grupo que consiste en hidrógeno, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, -C(O)R101, -C(O)OR101, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo, cada uno opcionalmente sustituido en forma independiente con uno o más sustituyentes R103 independientes; R2 es hidrógeno; R3 se selecciona entre el grupo que consiste en hidrógeno, alquilo, alquenilo, cicloalquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, -C(O)R101, -C(O)OR101, -C(O)NR101R102, -S(O)2R102, -SR101 y -S(O)2NR101R102, opcionalmente sustituido con uno o más sustituyentes R103 independientes; R4 se selecciona entre el grupo que consiste en alquilo, alquenilo, cicloalquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, -OR103, NR101R102, -C(O)R101, -C(O)OR101, -C(O)NR101R102, -alquilNR101R102, -S(O)2R102, -SR101 y -S(O)2NR101R102, opcionalmente sustituido con uno o más sustituyentes R103 independientes; o R3 y R4, junto con los átomos que conectan R3 y R4, forman un anillo mono, bicíclico o tricíclico, heterocíclico o carbocíclico, fusionado o no fusionado que está opcionalmente sustituido en forma independiente con uno o más sustituyentes R103; R5 se selecciona entre el grupo que consiste en alquilo, alquenilo, cicloalquilo, arilo, arilalquilo, heterocicloalquilo, heteroarilo, heteroarilalquilo, óxido (=O), -C(O)R101, -C(O)OR101, -C(O)NR101R102, -S(O)2R102, -SR101 y -S(O)2NR101R102; R6, R7, R8, R9, R10, R11, R12, R13 y R14 se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrógeno, ciano, -NO2, -OR101, hidroxi, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, -C(O)R101, -C(O)OR101, -C(O)NR101R102, -NR101R102, -NR101S(O)R102, -NR101C(O)R102, -S(O)2R102, -SR101 y -S(O)2NR101R102, cada uno opcionalmente sustituido en forma independiente con uno o más sustituyentes R103 independientes; o cualesquier dos o más sustituyentes seleccionados entre el grupo que consiste en R6, R7, R8, R9, R10, R11, R12, R13 y R14 junto con los átomos que los conectan, forman un anillo mono, bicíclico o tricíclico, heterocíclico o carbocíclico, fusionado o no fusionado que está opcionalmente sustituido en forma independiente con uno o más sustituyentes R103; y R101, R102 y R103 se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrógeno, ciano, -NO2, -OR104, hidroxi, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo, heteroarilalquilo, -C(O)R104, -C(O)OR104, -C(O)NR104R105, -NR104R105, -NR104S(O)2R105, -NR104C(O)R105, -S(O)2R104, -SR104 y -S(O)2NR104R105, cada uno opcionalmente sustituido en forma independiente con uno o más sustituyentes R103 independientes; o R101, R102, junto con los átomos que los conectan, forman un anillo mono, bicíclico o tricíclico, heterocíclico o carbocíclico, fusionado o no fusionado que está opcionalmente sustituido en forma independiente con uno o más sustituyentes R103; y R104 y R105 se seleccionan en forma independiente entre sí entre el grupo que consiste en hidrógeno, ciano, -NO2, hidroxi, hidroxialquilo, amino, alquilo, alquenilo, cicloalquilo, halógeno, alcoxi, alcoxialquilo, arilo, arilalquilo, heterocicloalquilo, heterocicloalquilalquilo, heteroarilo y heteroarilalquilo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2011/000298 WO2012113103A1 (en) | 2011-02-25 | 2011-02-25 | Asymmetric ureas and medical uses thereof |
US201161466070P | 2011-03-22 | 2011-03-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR085398A1 true AR085398A1 (es) | 2013-09-25 |
Family
ID=46719417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP120100611A AR085398A1 (es) | 2011-02-25 | 2012-02-24 | Ureas asimetricas y usos medicos de las mismas |
Country Status (39)
Country | Link |
---|---|
US (3) | US8658797B2 (es) |
EP (1) | EP2678017B1 (es) |
JP (1) | JP6077468B2 (es) |
KR (2) | KR20140014186A (es) |
CN (2) | CN103874492B (es) |
AP (1) | AP3768A (es) |
AR (1) | AR085398A1 (es) |
AU (1) | AU2012220531B2 (es) |
BR (1) | BR112013021566B1 (es) |
CA (1) | CA2820767C (es) |
CL (1) | CL2013002412A1 (es) |
CO (1) | CO6771450A2 (es) |
CY (1) | CY1118947T1 (es) |
DK (1) | DK2678017T3 (es) |
DO (1) | DOP2013000195A (es) |
EA (1) | EA027374B1 (es) |
EC (1) | ECSP13012893A (es) |
ES (1) | ES2628386T3 (es) |
GE (1) | GEP20156319B (es) |
HR (1) | HRP20170997T1 (es) |
HU (1) | HUE035039T2 (es) |
IL (1) | IL227941A (es) |
LT (1) | LT2678017T (es) |
MA (1) | MA34968B1 (es) |
ME (1) | ME02845B (es) |
MX (1) | MX347587B (es) |
MY (1) | MY164354A (es) |
NI (1) | NI201300070A (es) |
PE (1) | PE20141000A1 (es) |
PL (1) | PL2678017T3 (es) |
PT (1) | PT2678017T (es) |
RS (1) | RS56033B1 (es) |
SG (1) | SG192138A1 (es) |
SI (1) | SI2678017T1 (es) |
TN (1) | TN2013000346A1 (es) |
TW (1) | TWI579273B (es) |
UA (1) | UA113510C2 (es) |
WO (2) | WO2012113103A1 (es) |
ZA (1) | ZA201307071B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
AU2013364133B2 (en) | 2012-12-21 | 2018-10-11 | Aveo Pharmaceuticals, Inc. | Anti-GDF15 antibodies |
TWI690512B (zh) * | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
RU2686317C2 (ru) * | 2015-04-24 | 2019-04-25 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Замещенные 1,2,5-триметил- и 2,2,6,6-тетраметил-4-аминопиперидины, обладающие антиишемическим действием |
FI3390355T3 (fi) | 2016-03-22 | 2023-04-04 | Helsinn Healthcare Sa | Asymmetrisiä bentseenisulfonyyliureoita ja niiden lääketieteellisiä käyttöjä |
CN111182896A (zh) * | 2017-08-07 | 2020-05-19 | 国立大学法人广岛大学 | 脂肪性肝病的治疗剂以及肥胖症的治疗剂 |
EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
CN111132976B (zh) | 2017-08-21 | 2023-08-22 | 阿卡蒂亚药品公司 | 化合物、其盐和用于治疗疾病的方法 |
HUE058247T2 (hu) | 2017-12-11 | 2022-07-28 | Helsinn Healthcare Sa | (R)-3-(1-(2,3-Diklór-4-(pirazin-2-il)fenil)-2,2,2-trifluoretil)-1-metil-1-(1-metilpiperidin-4-il)karbamid fumarát sója, elõállítási eljárásai és alkalmazásai |
EP3542799A1 (en) * | 2018-03-22 | 2019-09-25 | Helsinn Healthcare SA | New centrally-active ghrelin agonist and medical uses thereof |
CA3221574A1 (en) | 2021-06-02 | 2022-12-08 | Helsinn Healthcare Sa | Piperidine urea derivatives for use as inotropic agents |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5285174A (en) * | 1976-01-05 | 1977-07-15 | Yoshitomi Pharmaceut Ind Ltd | Novel urea or thiourea derivatives |
AU7545894A (en) | 1993-09-02 | 1995-03-22 | Yamanouchi Pharmaceutical Co., Ltd. | Carbamate derivative and medicine containing the same |
WO1998006709A1 (en) | 1996-08-14 | 1998-02-19 | Takeda Chemical Industries, Ltd. | Cyclic urea compounds, their production and use as herbicides |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
CA2397981C (en) * | 2000-03-06 | 2010-12-21 | Acadia Pharmaceuticals, Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
US20030022891A1 (en) * | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
WO2002070479A1 (en) | 2001-03-01 | 2002-09-12 | Astrazeneca Ab | N-4-piperidinyl compounds as ccr5 modulators |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
US6673829B2 (en) * | 2001-09-14 | 2004-01-06 | Novo Nordisk A/S | Aminoazetidine,-pyrrolidine and -piperidine derivatives |
SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
SE0200919D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
JP2006505531A (ja) * | 2002-09-11 | 2006-02-16 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−4受容体作働薬としてのピペラジン尿素誘導体 |
AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
IN2009CH01478A (en) * | 2003-06-30 | 2009-08-21 | Sumitomo Chemical Co | Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst |
US7115767B2 (en) * | 2003-07-18 | 2006-10-03 | Abbott Laboratories | Tetraline derivatives as ghrelin receptor modulators |
CN1946699A (zh) * | 2004-02-10 | 2007-04-11 | 詹森药业有限公司 | 作为α4整联蛋白拮抗剂的哒嗪酮脲类 |
US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
GB0412865D0 (en) | 2004-06-09 | 2004-07-14 | Glaxo Group Ltd | Chemical compounds |
SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
SE0401971D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
EP1784390A2 (en) * | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
AU2005302669A1 (en) * | 2004-10-27 | 2006-05-11 | Neurogen Corporation | Diaryl ureas as CB1 antagonists |
WO2006068594A1 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | HETEROCYCLIC MCHr1 ANTAGONISTS AND THEIR USE IN THERAPY |
US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
WO2007029086A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
KR20080076916A (ko) * | 2005-11-01 | 2008-08-20 | 트랜스테크 파르마, 인크. | 치환된 아미드의 약학적 사용 |
AR058277A1 (es) * | 2005-12-09 | 2008-01-30 | Solvay Pharm Gmbh | N- sulfamoil - piperidin - amidas, composiciones farmaceuticas que las comprenden y procedimiento para su preparacion |
EP2043634A2 (en) | 2006-07-12 | 2009-04-08 | Merck & Co., Inc. | Substituted pyrazoles as ghrelin receptor antagonists |
JP2008042298A (ja) | 2006-08-02 | 2008-02-21 | Olympus Corp | 固体撮像装置 |
GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
WO2008141057A1 (en) * | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea |
GB0710863D0 (en) | 2007-06-06 | 2007-07-18 | Glaxo Group Ltd | Novel compounds |
GB0710865D0 (en) | 2007-06-06 | 2007-07-18 | Glaxo Group Ltd | Novel compounds |
US20110098322A1 (en) | 2007-08-06 | 2011-04-28 | The Regents Of The University Of California | Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase |
EP2200610B1 (en) * | 2007-09-21 | 2018-01-10 | Acadia Pharmaceuticals Inc. | Co-administration of pimavanserin with other agents |
UA100527C2 (en) * | 2007-10-10 | 2013-01-10 | Астразенека Аб | Benzothiazoles as ghrelin receptor modulators |
WO2009089659A1 (en) | 2008-01-18 | 2009-07-23 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
WO2009092293A1 (en) | 2008-01-18 | 2009-07-30 | Shanghai Targetdrug Co., Ltd. | Pyrollidine-based compounds |
USRE49686E1 (en) * | 2008-09-19 | 2023-10-10 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use of same |
WO2010111353A1 (en) * | 2009-03-25 | 2010-09-30 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
WO2011060397A1 (en) * | 2009-11-16 | 2011-05-19 | Schering Corporation | Substituted amino heterocycles useful as hiv antagonists |
WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
-
2011
- 2011-02-25 WO PCT/CN2011/000298 patent/WO2012113103A1/en active Application Filing
-
2012
- 2012-02-23 MA MA36252A patent/MA34968B1/fr unknown
- 2012-02-23 AU AU2012220531A patent/AU2012220531B2/en active Active
- 2012-02-23 PL PL12749383T patent/PL2678017T3/pl unknown
- 2012-02-23 CN CN201280008805.XA patent/CN103874492B/zh active Active
- 2012-02-23 DK DK12749383.1T patent/DK2678017T3/en active
- 2012-02-23 BR BR112013021566-6A patent/BR112013021566B1/pt active IP Right Grant
- 2012-02-23 KR KR1020137025184A patent/KR20140014186A/ko active IP Right Grant
- 2012-02-23 JP JP2013555559A patent/JP6077468B2/ja active Active
- 2012-02-23 AP AP2013007123A patent/AP3768A/en active
- 2012-02-23 PE PE2013001934A patent/PE20141000A1/es active IP Right Grant
- 2012-02-23 CN CN201611088800.9A patent/CN106995403B/zh active Active
- 2012-02-23 SI SI201230981A patent/SI2678017T1/sl unknown
- 2012-02-23 ES ES12749383.1T patent/ES2628386T3/es active Active
- 2012-02-23 RS RS20170546A patent/RS56033B1/sr unknown
- 2012-02-23 MX MX2013006974A patent/MX347587B/es active IP Right Grant
- 2012-02-23 SG SG2013056775A patent/SG192138A1/en unknown
- 2012-02-23 KR KR1020187017910A patent/KR101907573B1/ko active IP Right Grant
- 2012-02-23 EA EA201300946A patent/EA027374B1/ru unknown
- 2012-02-23 LT LTEP12749383.1T patent/LT2678017T/lt unknown
- 2012-02-23 MY MYPI2013003013A patent/MY164354A/en unknown
- 2012-02-23 CA CA2820767A patent/CA2820767C/en active Active
- 2012-02-23 PT PT127493831T patent/PT2678017T/pt unknown
- 2012-02-23 UA UAA201311289A patent/UA113510C2/uk unknown
- 2012-02-23 HU HUE12749383A patent/HUE035039T2/en unknown
- 2012-02-23 ME MEP-2017-123A patent/ME02845B/me unknown
- 2012-02-23 GE GEAP201213239A patent/GEP20156319B/en unknown
- 2012-02-23 WO PCT/US2012/026315 patent/WO2012116176A2/en active Application Filing
- 2012-02-23 EP EP12749383.1A patent/EP2678017B1/en active Active
- 2012-02-24 AR ARP120100611A patent/AR085398A1/es active IP Right Grant
- 2012-02-24 TW TW101106171A patent/TWI579273B/zh active
- 2012-02-24 US US13/404,165 patent/US8658797B2/en active Active
-
2013
- 2013-08-13 IL IL227941A patent/IL227941A/en active IP Right Grant
- 2013-08-15 NI NI201300070A patent/NI201300070A/es unknown
- 2013-08-16 TN TNP2013000346A patent/TN2013000346A1/fr unknown
- 2013-08-21 CL CL2013002412A patent/CL2013002412A1/es unknown
- 2013-08-23 DO DO2013000195A patent/DOP2013000195A/es unknown
- 2013-09-19 ZA ZA2013/07071A patent/ZA201307071B/en unknown
- 2013-09-24 EC EC2013012893A patent/ECSP13012893A/es unknown
- 2013-09-24 CO CO13226995A patent/CO6771450A2/es unknown
-
2014
- 2014-01-08 US US14/150,360 patent/US9751836B2/en active Active
-
2017
- 2017-06-19 CY CY20171100635T patent/CY1118947T1/el unknown
- 2017-06-30 HR HRP20170997TT patent/HRP20170997T1/hr unknown
- 2017-07-30 US US15/663,761 patent/US10407390B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
AR085958A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer | |
AR089019A1 (es) | Derivados modificados de 4-fenil-piridina | |
AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
AR085316A1 (es) | Derivados de pirrolo[2,3-b]piridina, utiles para la modulacion de quinasas | |
AR092270A1 (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR104025A1 (es) | Carbamatos de piperazina como moduladores de magl y/o abhd6, procesos para su preparación y composiciones farmacéuticas | |
AR073574A1 (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
AR099363A1 (es) | Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR093518A1 (es) | Compuestos de pirrolpirimidina como inhibidores de quinasas | |
AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
AR082885A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR089175A1 (es) | Inhibidores de pak para el tratamiento de trastornos de proliferacion celular | |
AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
AR100418A1 (es) | Compuestos y composiciones para inducir condrogénesis | |
PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
BR112015032637A2 (pt) | derivados de pirrolopiridina ou pirazolopiridina | |
AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
AR093077A1 (es) | ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |